Jazz Pharmaceuticals, Inc. (JAZZ) - NASDAQ
  • Tue, Jul. 19, 10:50 AM
    • Prompted by moderating growth from traditional drug sales, large cap drug/biotech firms have their sights set on developers of cancer therapies, in particular immunotherapies, to boost both their top and bottom lines. Roche (OTCQX:RHHBY -1.5%), Amgen (AMGN +0.1%), Sanofi (SNY -1.3%) and Gilead Sciences (GILD -1.2%) are all actively on the prowl for acquisitions.
    • Medivation (MDVN +0.1%), with its prostate cancer drug Xtandi (enzalutamide), is currently in play. Sanofi has been the most aggressive with two unsuccessful bids, but Pfizer (PFE) and Celgene (CELG -0.6%) are supposedly interested.
    • Analysts say Incyte (INCY -0.4%), with polycythemia vera and myelofibrosis drug Jakafi (ruxolitinib), and Seattle Genetics (SGEN -0.8%), with lymphoma drug Adcetris (brentuximab vedotin), are the most attractive takeover targets.
    • Recent transactions include AbbVie's (ABBV -0.3%) buyout of Stemcentryx, Jazz Pharmaceuticals' (JAZZ -0.8%) takeout of Celator Pharmaceuticals and Bristol-Myers Squibb's (BMY -0.2%) acquisition of Cormorant Pharmaceuticals.
    | Tue, Jul. 19, 10:50 AM | 7 Comments
  • Tue, Jul. 12, 7:22 AM
    • Jazz Pharmaceuticals (NASDAQ:JAZZ) announces the results of its tender offer to purchase all of the outstanding shares of common stock of Celator Pharmaceuticals (NASDAQ:CPXX) at $30.25 per share. The tender offer is being effected by Jazz Pharmaceuticals' indirect wholly-owned subsidiary, Plex Merger Sub.
    • A total of 36.5M shares of Celator common stock had been validly tendered, representing ~81.13% of its outstanding shares. Additionally Notices of Guaranteed Delivery have been delivered with respect to 2M additional shares, representing another 4.48%.
    • In late May, Jazz announced its intent to acquire Celator for $1.5B.
    | Tue, Jul. 12, 7:22 AM
  • Fri, Jul. 1, 10:08 AM
    • Invitae (NYSE:NVTA) initiated with Hold rating with an $8.50 (18% upside) price target by Benchmark.
    • Jazz Pharmaceuticals (NASDAQ:JAZZ) initiated with Outperform rating and $190 (33% upside) price target by BMO.
    • Pacira Pharmaceuticals (NASDAQ:PCRX) initiated with Underperform rating and $36 (4% upside) price target by BMO.
    • Mallinckrodt (NYSE:MNK) initiated with Outperform rating and $84 (35% upside) price target by BMO.
    • Horizon Pharma plc (NASDAQ:HZNP) initiated with Outperform rating and $29 (71% upside) price target by BMO.
    • Regeneron Pharmaceuticals (NASDAQ:REGN) initiated with an Outperform rating and $400 (13% upside) price target by Bernstein.
    • Biogen (NASDAQ:BIIB) initiated with an Outperform rating and $282 (15% upside) price target by Bernstein.
    • Amgen (NASDAQ:AMGN) initiated with Market Perform rating and $161 (5% upside) price target by Bernstein.
    • Lannett Company (NYSE:LCI) initiated with Hold rating and $26 (5% upside) price target by Deutsche Bank.
    • OpGen (NASDAQ:OPGN) initiated with Buy rating and $2.50 (66% upside) price target by Rodman & Renshaw.
    • Valeant Pharmaceuticals (NYSE:VRX) initiated with Market Perform rating and $26 (22% upside) price target by BMO.
    • Neurocrine Biosciences (NASDAQ:NBIX) initiated with Outperform rating and $80 (75% upside) price target by H.C. Wainwright.
    • Healthstream (NASDAQ:HSTM) initiated with Outperform rating and $30 (12% upside) price target by Barrington Research.
    • Neurometrix (NASDAQ:NURO) initiated with Buy rating and $4.50 (165% upside) price target by Rodman & Renshaw.
    • Vascular Biogenics (NASDAQ:VBLT) initiated with Buy rating and $11 (139% upside) price target by H.C. Wainwright.
    | Fri, Jul. 1, 10:08 AM | 6 Comments
  • Wed, Jun. 15, 5:32 PM
    | Wed, Jun. 15, 5:32 PM | 13 Comments
  • Tue, Jun. 14, 4:37 PM
    • Jazz Pharmaceuticals (NASDAQ:JAZZ) will host a conference call and audio webcast on June 20 at 4:30 pm ET to update investors on JZP-110, its Phase 3-stage wake-promoting agent under development for the treatment of excessive sleepiness in adults with narcolepsy or obstructive sleep apnea.
    • Jazz acquired the rights to the drug from Aerial BioPharma in early 2014.
    | Tue, Jun. 14, 4:37 PM | 1 Comment
  • Fri, Jun. 10, 7:19 AM
    • Boston Scientific (NYSE:BSX) initiated with Buy rating and $26 (13% upside) price target by Guggenheim Securities.
    • Zimmer Biomet Holdings (NYSE:ZBH) initiated with Neutral rating and $140 (18% upside) price target by Guggenheim Securities.
    • Edwards Lifesciences (NYSE:EW) initiated with Neutral rating and $120 (18% upside) price target by Guggenheim Securities.
    • Oncobiologics (Pending:ONS) initiated with Buy rating and $15 (218% upside) price target by Cantor Fitzgerald.
    • Walgreens Boots Alliance (NASDAQ:WBA) reinstated with Buy rating and $95 (20% upside) price target by Bank of America.
    • Goldman Sachs initiates coverage of specialty pharma with a Neutral rating: Buy: Jazz Pharma (NASDAQ:JAZZ) - $196 (26% upside) price target, Horizon Pharma (NASDAQ:HZNP) - $24 (30% upside) price target; Neutral: Endo International (NASDAQ:ENDP) - $20 (11% upside) price target, Mallinckrodt (NYSE:MNK) - $73 (17% upside) price target, Momenta Pharmaceuticals (NASDAQ:MNTA) - $14 (19% upside) price target; Concordia Healthcare (NASDAQ:CXRX) - $32 (31% upside) price target; Sell: Impax Laboratories (NASDAQ:IPXL) - $33 (2% downside risk) price target.
    • Biocept (NASDAQ:BIOC) initiated with Buy rating and $1.20 (71% upside) price target by Roth Capital.
    • Seres Therapeutics (NASDAQ:MCRB) initiated with Outperform rating and $40 (22% upside) price target by Cowen & Company.
    • Omeros (NASDAQ:OMER) initiated with Buy rating and $21 (94% upside) price target by Cantor Fitzgerald.
    • Glaukos (NYSE:GKOS) initiated with Buy rating and $35 (30% upside) price target by Cantor Fitzgerald.
    • Shire plc (NASDAQ:SHPG) initiated with Overweight rating and GBX5,600 (34% upside) price target by Morgan Stanley.
    | Fri, Jun. 10, 7:19 AM
  • Tue, May 31, 3:49 AM
    • Jazz Pharmaceuticals (NASDAQ:JAZZ) is nearing a deal to buy Celator (NASDAQ:CPXX) for $1.5B, or about double its market cap - a huge premium even in biotechnology, where acquirers often pay for promising new drugs.
    • About three months ago, Celator said its Vyxeos treatment helped older high-risk patients with a deadly form of leukemia live longer than those who received the standard of care regimen, sending its stock price soaring.
    • CPXX +78.3% premarket
    • Update: Jazz announces that it will acquire Celator for $30.25 per share in cash or ~$1.5B.
    | Tue, May 31, 3:49 AM | 16 Comments
  • Tue, May 10, 4:17 PM
    • Jazz Pharmaceuticals (NASDAQ:JAZZ): Q1 EPS of $2.26 misses by $0.05.
    • Revenue of $336.01M (+8.6% Y/Y) misses by $2.85M.
    • Press Release
    | Tue, May 10, 4:17 PM | 1 Comment
  • Mon, May 9, 5:35 PM
  • Fri, Apr. 29, 4:12 PM
    • Medtronic (MDT -0.8%) initiated with Buy rating and $93 (18% upside) price target by SunTrust Robinson Humphrey.
    • Celator Pharmaceuticals (CPXX +1.5%) initiated with Buy rating and $23 (53% upside) price target by Stifel Nicolaus.
    • Caladrius Biosciences (CLBS -1%) upgraded to Buy from Neutral by H.C. Wainwright with a price target of $1.25 (81% upside).
    • Insulet (PODD -0.6%) upgraded to Outperform from Market Perform by William Blair with a $40 (21% upside) price target.
    • Alexion Pharmaceuticals (ALXN -2.3%) upgraded to Outperform from Market Perform by BMO Capital with a $168 (21% upside) price target.
    • ResMed (RMD -1.2%) upgraded to Neutral from Underperform by Macquarie. Price target lowered to $57 (2% upside) from $65.
    • Stryker (SYK -0.5%) upgraded to Buy from Neutral by Sterne Agee CRT with $130 (19% upside) price target.
    • Jazz Pharmaceuticals (JAZZ -0.9%) upgraded to Buy from Neutral by SunTrust Robinson Humphrey. Price target raised to $200 (32% upside) from $164.
    • Rigel Pharmaceuticals (RIGL -1.7%) upgraded to Overweight from Neutral by JP Morgan with a $5 price target.
    • Novartis (NVS -1.1%) upgraded to Equal Weight from Underweight by Barclays.
    • Molina Healthcare (MOH -19.4%) downgraded to Neutral from Buy by UBS. Price target lowered to $54 (4% upside) from $76.
    • St. Jude Medical (STJ -2%) downgraded to Neutral from Overweight by JP Morgan. Price target raised to $82.50 (9% upside) from $66.
    • Stericycle (SRCL -21.5%) downgraded to Underperform from Sector Perform by RBC. Price target lowered to $96 (1% upside) from $119.
    • Sarepta Therapeutics (SRPT +2.8%) downgraded to Underperform from Hold by Jefferies with a price target of $7 (51% downside risk). Downgraded to Underweight from Neutral by Piper Jaffray. Price target lowered to $6 (57% downside risk) from $15.
    • Perrigo (PRGO +0.3%) downgraded to Neutral from Buy by BTIG Research. Priced target removed.
    • Trovagene (TROV -3.6%) downgraded to Hold from Buy by Cantor Fitzgerald with a $6 (50% upside) price target.
    • Community Health Systems (CYH -4.6%) downgraded to Underperform from Market Perform by Raymond James with a $19 (0% upside) price target.
    | Fri, Apr. 29, 4:12 PM | 5 Comments
  • Wed, Mar. 30, 12:37 PM
    • The FDA approves Jazz Pharmaceuticals' (JAZZ +2.5%) Defitelio (defibrotide sodium) for the treatment of adults and children who develop hepatic veno-occlusive disease (VOD), with additional kidney or lung problems, following hematopoietic stem cell transplantation (HSCT). This is the first FDA-approved therapy for the rare and life-threatening condition.
    • In clinical studies supporting the New Drug Application (NDA), 38 - 45% patients with hepatic VOD and liver or kidney abnormalities were still alive 100 days after HSCT, compared to 21 - 31% of patients who received other supportive care or interventions (according to published literature).
    • Serious adverse events reported included bleeding and allergic reactions.
    • Hepatic VOD occurs when some of the veins in the liver become blocked, causing swelling and decreased blood flow in the liver leading to potential organ damage. In extreme cases (fewer than 2% of HSCT patients), the person may experience kidney and/or lung failure.
    | Wed, Mar. 30, 12:37 PM
  • Tue, Feb. 23, 4:08 PM
    • Jazz Pharmaceuticals (NASDAQ:JAZZ): Q4 EPS of $2.60 in-line.
    • Revenue of $340.9M (+3.9% Y/Y) misses by $8.93M.
    • Shares +0.5%.
    • Press Release
    | Tue, Feb. 23, 4:08 PM
  • Mon, Feb. 22, 5:35 PM
  • Nov. 10, 2015, 9:13 AM
    | Nov. 10, 2015, 9:13 AM | 12 Comments
  • Nov. 9, 2015, 4:08 PM
    • Jazz Pharmaceuticals (NASDAQ:JAZZ): Q3 EPS of $2.52 misses by $0.04.
    • Revenue of $340.9M (+11.2% Y/Y) misses by $7.25M.
    • Shares -6.4%.
    | Nov. 9, 2015, 4:08 PM
  • Nov. 8, 2015, 5:35 PM
Company Description
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. Its product... More
Sector: Healthcare
Industry: Biotechnology
Country: United States